Baxter Locks Up European Rights To Onconova’s Late-Stage Cancer Drug Rigosertib
This article was originally published in The Pink Sheet Daily
For an myelodysplastic syndrome and pancreatic cancer drug, the diversified pharma and device company paid $50 million upfront, plus a generous $515 million in milestones that could pay out before the drug is even commercialized.
You may also be interested in...
Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates
Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.
Gilead Takes Calistoga To Boost Cancer Effort
Gilead Sciences Inc.’s recent acquisition of Calistoga Pharmaceuticals Inc. for $375 million up front is the richest deal yet for PI3K inhibitors, an emerging class of cancer drugs that many companies large and small are hotly pursuing.
Craig Venter Wants To Extend Your Life (And Own Your Data)
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.